Why the study?
Does B-type natriuretic peptide (BNP) blood testing identify coronary artery disease in patients with symptomatic chest pain or asymptomatic high-risk patients?
Does B-type natriuretic peptide (BNP) blood testing identify coronary artery disease in patients with symptomatic chest pain or asymptomatic high-risk patients?
BNP testing may serve as a simple pre-screening tool to identify patients with symptomatic or asymptomatic CAD who require more definitive testing.
May support BNP for CAD pre-screening but should not change practice; leaves open need for prospective validation.
A common key question in clinical medicine is whether coronary artery disease (CAD) is present in a patient. This applies not only to patients with symptomatic chest pain, but also to those at high risk of sudden unexpected death due to asymptomatic CAD, such as diabetics. In both groups of patients, it would be of great benefit if a simple blood test could identify those most likely to have CAD. Such individuals could then be selected for more definitive but more invasive tests for CAD, such as angiography, exercise testing, etc. In addition to its established role in diagnosing heart failure, it appears that BNP may fulfil this function of pre-screening for both symptomatic and asymptomatic CAD. We review the evidence for this new prospect, which has the potential to reduce cardiac deaths by using a simple blood test to better target cardioprotective strategies to those who most need them.
No takes yet. Share an insight, caveat, or question.
Struthers et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: